BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 22752858)

  • 1. Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections.
    Weiss K; Allgren RL; Sellers S
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S110-5. PubMed ID: 22752858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of fidaxomicin compared with oral vancomycin for the treatment of adults with Clostridium difficile-associated diarrhea: data from the OPT-80-003 and OPT-80-004 studies.
    Chen LF; Anderson DJ
    Future Microbiol; 2012 Jun; 7(6):677-83. PubMed ID: 22702523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
    Crook DW; Walker AS; Kean Y; Weiss K; Cornely OA; Miller MA; Esposito R; Louie TJ; Stoesser NE; Young BC; Angus BJ; Gorbach SL; Peto TE;
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S93-103. PubMed ID: 22752871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Crawford T; Huesgen E; Danziger L
    Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
    Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
    J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
    Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
    Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.
    Figueroa I; Johnson S; Sambol SP; Goldstein EJ; Citron DM; Gerding DN
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S104-9. PubMed ID: 22752857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-Associated Diarrhea: A Phase 2a Multicenter Clinical Trial.
    O'Gorman MA; Michaels MG; Kaplan SL; Otley A; Kociolek LK; Hoffenberg EJ; Kim KS; Nachman S; Pfefferkorn MD; Sentongo T; Sullivan JE; Sears P
    J Pediatric Infect Dis Soc; 2018 Aug; 7(3):210-218. PubMed ID: 28575523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).
    Wolf J; Kalocsai K; Fortuny C; Lazar S; Bosis S; Korczowski B; Petit A; Bradford D; Croos-Dabrera R; Incera E; Melis J; van Maanen R
    Clin Infect Dis; 2020 Dec; 71(10):2581-2588. PubMed ID: 31773143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fidaxomicin for the treatment of
    Skinner AM; Scardina T; Kociolek LK
    Future Microbiol; 2020 Jul; 15(11):967-979. PubMed ID: 32715754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.
    Tannock GW; Munro K; Taylor C; Lawley B; Young W; Byrne B; Emery J; Louie T
    Microbiology (Reading); 2010 Nov; 156(Pt 11):3354-3359. PubMed ID: 20724385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.
    Sullivan KM; Spooner LM
    Ann Pharmacother; 2010 Feb; 44(2):352-9. PubMed ID: 20071495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fidaxomicin--the new drug for Clostridium difficile infection.
    Vaishnavi C
    Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.
    Biswas JS; Patel A; Otter JA; Wade P; Newsholme W; van Kleef E; Goldenberg SD
    J Hosp Infect; 2015 Jul; 90(3):267-70. PubMed ID: 25728208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.
    Petrella LA; Sambol SP; Cheknis A; Nagaro K; Kean Y; Sears PS; Babakhani F; Johnson S; Gerding DN
    Clin Infect Dis; 2012 Aug; 55(3):351-7. PubMed ID: 22523271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fidaxomicin, a new treatment for Clostridium difficile infections.
    Epstein L; Golan Y
    Drugs Today (Barc); 2012 Feb; 48(2):101-8. PubMed ID: 22384450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile.
    Eyre DW; Babakhani F; Griffiths D; Seddon J; Del Ojo Elias C; Gorbach SL; Peto TE; Crook DW; Walker AS
    J Infect Dis; 2014 May; 209(9):1446-51. PubMed ID: 24218500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile.
    Turner NA; Warren BG; Gergen-Teague MF; Addison RM; Addison B; Rutala WA; Weber DJ; Sexton DJ; Anderson DJ
    Clin Infect Dis; 2022 Mar; 74(4):648-656. PubMed ID: 34017999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.